Systemic Diseases with Renal Manifestations

Primary Care - Clinics in Office Practice

Volumn 35, Issue 2, 2008, Pages 297-328

  Rajashekar, Asha ^a   Perazella, Mark A ^a   Crowley, Susan ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALDOSTERONE ANTAGONIST; AMYLIN DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIRETROVIRUS AGENT; BUMETANIDE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; FUROSEMIDE; GLIPIZIDE; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIXIVAPTAN; METFORMIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NESIRITIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; THIAZIDE DIURETIC AGENT; TOLVAPTAN; TORASEMIDE; UNINDEXED DRUG; VASOPRESSIN ANTAGONIST;

AMYLOIDOSIS; AVASCULAR NECROSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DIABETIC NEPHROPATHY; DIALYSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPROTEINEMIA; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERTENSION; IMMUNE COMPLEX DISEASE; IMMUNOGLOBULIN A NEPHROPATHY; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY AMYLOIDOSIS; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FAILURE; LACTIC ACIDOSIS; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MONOCLONAL IMMUNOGLOBULINEMIA; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OTOTOXICITY; OVARY INSUFFICIENCY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SCREENING; SMOKING CESSATION; SYSTEMIC DISEASE; THROMBOTIC THROMBOCYTOPENIC PURPURA; ULTRAFILTRATION; UNSPECIFIED SIDE EFFECT; URINALYSIS;

DIABETIC NEPHROPATHIES; HEART FAILURE; HIV INFECTIONS; HUMANS; KIDNEY DISEASES; LIVER DISEASES; LUPUS NEPHRITIS; MASS SCREENING; PROGNOSIS; UNITED STATES;

EID: 43649098164     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pop.2008.01.006     Document Type: Review

References (132)

1. USRDS-ADR 2007. Available at:. http://www.usrds.org/adr.htm Accessed November 6, 2007
2. CDC's diabetes program-data & trends-1997-2005. Available at: http://www.cdc.gov/diabetes/statistics/incidence/fig1.htm. Accessed November 11, 2007.
3. Vora J.P., and Ibrahim Hisham A. Clinical manifestations and natural history of diabetic nephropathy. In: Johnson R.J., and Feehally J. (Eds). Comprehensive clinical nephrology. 2nd edition (2003), Mosby, Edinburgh (NY) 425
4. Remuzzi G., Schieppati A., and Ruggenenti P. Clinical practice. nephropathy in patients with type 2 diabetes. [see comment]. N Engl J Med 346 (2002) 1145-1151
5. Nelson R.G., Bennett P.H., Beck G.J., et al. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. N Engl J Med 335 (1996) 1636-1642
6. Molitch M.E. Management of early diabetic nephropathy. Am J Med 102 (1997) 392-398
7. Christensen P.K., Larsen S., Horn T., et al. Causes of albuminuria in patients with type 2 diabetes without diabetic retinopathy. Kidney Int 58 (2000) 1719-1731
8. Wolf G., and Ritz E. Diabetic nephropathy in type 2 diabetes prevention and patient management. J Am Soc Nephrol 14 (2003) 1396-1405
9. Nicholls A.J. The impact of atherosclerotic renovascular disease on diabetic renal failure. Diabet Med 19 (2002) 889-894
10. American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care 30 (2007) S4-S41
11. Gross J., deAzevedo M., Silveiro S., et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 28 (2005) 164-176
12. Caramori M.L., Fioretto P., and Mauer M. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions. Diabetes 52 (2003) 1036-1040
13. Gaede P., Vedel P., Parving H.H., et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the steno type 2 randomised study. Lancet 353 (1999) 617-622
14. Levinsky N.G. Specialist evaluation in chronic kidney disease: too little, too late. Ann Intern Med 137 (2002) 542-543
15. Becker B.N., Rush S.H., Dykstra D.M., et al. Preemptive transplantation for patients with diabetes-related kidney disease. Arch Intern Med 166 (2006) 44-48
16. Kidney Disease Outcomes Quality Iniative. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 49 (2007) S62-S73
17. Alaveras A.E., Thomas S.M., Sagriotis A., et al. Promoters of progression of diabetic nephropathy: the relative roles of blood glucose and blood pressure control. Nephrol Dial Transplant 12 Suppl 2 (1997) 71-74
18. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
19. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. J Am Med Assoc 290 (2003) 2159-2167
20. UK Prospective Diabetes Study (UKPDS) group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
21. Fioretto P., Bruseghin M., Berto I., et al. Renal protection in diabetes: role of glycemic control. J Am Soc Nephrol 17 (2006) S86-S89
22. Wu M., Yu C., Yang C., et al. Poor pre-dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis. Nephrol Dial Transplant 12 (1997) 2105-2110
23. Sarafidis P.A., and Bakris G.L. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int 70 (2006) 1223-1233
24. Nissen S., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
25. Kiryluk K., and Isom R. Thiazolidinediones and fluid retention. Kidney Int 72 (2007) 762-768
26. Tucker M. Internal medicine news. Available at:. http://www.einternalmedicinenews.com/search/quick Accessed November 11, 2007
27. Lewis E., Hunsicker L., Bain R., et al., The Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329 (1993) 1456-1462
28. Parving H.H., Hommel E., Jensen B.R., et al. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int 60 (2001) 228-234
29. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998) 703-713
30. Viberti G., Mogensen C.E., Groop L.C., et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. J Am Med Assoc 271 (1994) 275-279
31. Hovind P., Rossing P., Tarnow L., et al. Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively. Kidney Int 60 (2001) 277-283
32. Jacobsen P., Andersen S., Rossing K., et al. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 63 (2003) 1874-1880
33. Ravid M., Brosh D., Levi Z., et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. a randomized, controlled trial. Ann Intern Med 128 (1998) 982-988
34. Lewis E., Hunsicker L., Clarke W., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
35. Brenner B., Cooper M., deZeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
36. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. J Am Med Assoc 289 (2003) 2560-2572
37. Lewis E.J. Treating hypertension in the patient with overt diabetic nephropathy. Semin Nephrol 27 (2007) 182-194
38. Cases A., and Coll E. Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int Suppl 99 (2005) S87-S93
39. Fried L.F., Orchard T.J., and Kasiske B.L. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 59 (2001) 260-269
40. Liao J.K., and Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45 (2005) 89-118
41. Seligman V.A., Lum R.F., Olson J.L., et al. Demographic differences in the development of lupus nephritis: a retrospective analysis. Am J Med 112 (2002) 726-729
42. Arbuckle M.R., McClain M.T., Rubertone M.V., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349 (2003) 1526-1533
43. Mok C.C. Prognostic factors in lupus nephritis. Lupus 14 (2005) 39-44
44. Contreras G., Roth D., Pardo V., et al. Lupus nephritis: a clinical review for practicing nephrologists. Clin Nephrol 57 (2002) 95-107
45. Appel G., Pirani C., and D'Agati V. Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol 4 (1994) 1499-1515
46. Korbet S.M., Schwartz M.M., Evans J., et al., For the Collaborative Study Group. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol 18 (2007) 244-254
47. Cameron J.S. Lupus nephritis. J Am Soc Nephrol 10 (1999) 413-424
48. Weening J.J., D'Agati V.D., Schwartz M.M., et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65 (2004) 521-530
49. Austin H.A., and Illei G.G. Membranous lupus nephritis. Lupus 14 (2005) 65-71
50. Hayslett J.P. Maternal and fetal complications in pregnant women with systemic lupus erythematosus. Am J Kidney Dis 17 (1991) 123-126
51. Yasmeen S., Wilkins E.E., Field N.T., et al. Pregnancy outcomes in women with systemic lupus erythematosus. J Matern Fetal Med 10 (2001) 91-96
52. Kasitanon N., Magder L.S., and Petri M. Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore) 85 (2006) 147-156
53. Zimmerman R., Radhakrishnan J., Valeri A., et al. Advances in the treatment of lupus nephritis. Annu Rev Med 52 (2001) 63-78
54. Ponticelli C. New therapies for lupus nephritis. Clin J Am Soc Nephrol 1 (2006) 863-868
55. Steinberg A.D. The treatment of lupus nephritis. Kidney Int 30 (1986) 769-787
56. Houssiau F.A., Vasconcelos C., D'Cruz D., et al. Immunosuppressive therapy in lupus nephritis: the euro-lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46 (2002) 2121-2131
57. Zhu B., Chen N., Lin Y., et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 22 (2007) 1933-1942
58. Asanuma Y., Oeser A., Shintani A.K., et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 349 (2003) 2407-2415
59. Costanzo M.R., Guglin M.E., Saltzberg M.T., et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 49 (2007) 675-683
60. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Available at:. http://circ.ahajournals.org/cgi/content/full/CIRCULATIONAHA.106.179918 Accessed October 23, 2007
61. Fedele F., De Luca L., and Gheorghiade M. Current perspectives the cardiorenal syndrome: recognition and treatment. Ital Heart J 6 (2005) 941-945
62. Francis G. Acute decompensated heart failure: the cardiorenal syndrome. Cleve Clin J Med 73 (2006) S8-S13
63. Geisberg C., and Butler J. Addressing the challenges of cardiorenal syndrome. [see comment]. Cleve Clin J Med 73 (2006) 485-491
64. Heywood J.T. The cardiorenal syndrome: lessons from the ADHERE database and treatment options. Heart Fail Rev 9 (2004) 195-201
65. Makaritsis K.P., Liakopoulos V., Leivaditis K., et al. Adaptation of renal function in heart failure. Ren Fail 28 (2006) 527-535
66. Schrier R.W. Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor?. J Am Coll Cardiol 47 (2006) 1-8
67. Gottlieb S., Abraham W., Butler J., et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 8 (2002) 136-141
68. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
69. Ljungman S., Kjekshus J., and Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] trial). Am J Cardiol 70 (1992) 479-487
70. Brewster U.C., Setaro J.F., and Perazella M.A. The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci 326 (2003) 15-24
71. Jong P., Demers C., McKelvie R., et al. Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol 39 (2002) 463-470
72. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. Circulation 112 (2005) e154-e235
73. Pasquale P.D., Sarullo F.M., and Paterna S. Novel strategies: challenge loop diuretics and sodium management in heart failure-part I. Congest Heart Fail 13 (2007) 93-98
74. Vanderheyden M., Bartunek J., and Goethals M. Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail 6 (2004) 261-268
75. Mentzer Jr. R.M., Oz M.C., Sladen R.N., et al. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA trial. J Am Coll Cardiol 49 (2007) 716-726
76. Colucci W.S., Elkayam U., Horton D.P., et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 343 (2000) 246-253
77. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. J Am Med Assoc 287 (2002) 1531-1540
78. Heart Failure Society of America. IV vasodilators. Available at:. http://www.heartfailureguideline.com/index.cfm?id=142&s=1 Accessed October 27, 2007
79. Sackner-Bernstein J.D., Kowalski M., Fox M., et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. J Am Med Assoc 293 (2005) 1900-1905
80. Sackner-Bernstein J.D., Skopicki H.A., and Aaronson K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111 (2005) 1487-1491
81. LeJemtel T., and Serrano C. Vasopressin dysregulation: hyponatremia, fluid retention and congestive heart failure. Int J Cardiol 120 (2007) 1-9
82. Goldsmith S., and Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 46 (2005) 1785-1791
83. Konstam M.A., Gheorghiade M., Burnett Jr. J.C., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. J Am Med Assoc 297 (2007) 1319-1331
84. Gheorghiade M., Konstam M.A., Burnett Jr. J.C., et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. J Am Med Assoc 297 (2007) 1332-1343
85. UNAIDS. HIV and AIDS statistics. Available at:. http://www.unaids.org/en/HIV_data/epi2006/default.asp Accessed September 4, 2007
86. Rao T.K., Filippone E.J., Nicastri A.D., et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med 310 (1984) 669-673
87. Eggers P.W., and Kimmel P.L. Is there an epidemic of HIV infection in the US ESRD program?. J Am Soc Nephrol 15 (2004) 2477-2485
88. Szczech L.A., Gange S.J., van der Horst C., et al. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int 61 (2002) 195-202
89. Franceschini N., Napravnik S., Eron J.J., et al. Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int 67 (2005) 1526-1531
90. Izzedine H., Launay-Vacher V., and Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 45 (2005) 804-817
91. Kimmel P.L. The nephropathies of HIV infection: pathogenesis and treatment. Curr Opin Nephrol Hypertens 9 (2000) 117-122
92. D'Agati V., and Appel G.B. HIV infection and the kidney. J Am Soc Nephrol 8 (1997) 138-152
93. Winston J.A., Klotman M.E., and Klotman P.E. HIV-associated nephropathy is a late, not early, manifestation of HIV-1 infection. Kidney Int 55 (1999) 1036-1040
94. Kimmel P.L., Barisoni L., and Kopp J.B. Pathogenesis and treatment of HIV-associated renal diseases: lessons from clinical and animal studies, molecular pathologic correlations, and genetic investigations. Ann Intern Med 139 (2003) 214-226
95. Becker S., Fusco G., Fusco J., et al. Collaborations in HIV Outcomes Research/US Cohort. HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study. Clin Infect Dis 39 (2004) S267-S275
96. Gupta S.K., Eustace J.A., Winston J.A., et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 40 (2005) 1559-1585
97. Ross M.J., and Klotman P.E. Recent progress in HIV-associated nephropathy. J Am Soc Nephrol 13 (2002) 2997-3004
98. Schwartz E.J., Szczech L.A., Ross M.J., et al. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol 16 (2005) 2412-2420
99. Kumar M.S., Sierka D.R., Damask A.M., et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int 67 (2005) 1622-1629
100. Abbott K., Swanson S.J., Agodoa L.C., et al. Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression. J Am Soc Nephrol 15 (2004) 1633-1639
101. Selik R.M., Byers Jr. R.H., and Dworkin M.S. Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr 29 (2002) 378-387
102. Jayasekara D., Aweeka F.T., Rodriguez R., et al. Antiviral therapy for HIV patients with renal insufficiency. J Acquir Immune Defic Syndr 21 (1999) 384-395
103. Mocroft A., Kirk O., Gatell J., et al. Chronic renal failure among HIV-1-infected patients. AIDS 21 (2007) 1119-1127
104. Berns J.S., and Kasbekar N. Highly active antiretroviral therapy and the kidney: an update on antiretroviral medications for nephrologists. Clin J Am Soc Nephrol 1 (2006) 117-129
105. Said S.M., Nasr S.H., Samsa R., et al. Nephrotoxicity of antiretroviral therapy in an HIV-infected patient. Kidney Int 71 (2007) 1071-1075
106. Cattelan A.M., Trevenzoli M., Naso A., et al. Severe hypertension and renal atrophy associated with indinavir. Clin Infect Dis 30 (2000) 619-621
107. AIDSinfo site search -guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents October 10, 2006. Available at:. http://aidsinfo.nih.gov/search/sitesearch.asp?zoom_query=Guidelines for the use of antiretroviral agents in HIV-1-Infected adults &1=Search&zoom_cat=1 Accessed September 3, 2007
108. Lhotta K. Beyond hepatorenal syndrome: glomerulonephritis in patients with liver disease. Semin Nephrol 22 (2002) 302-308
109. Newell G.C. Cirrhotic glomerulonephritis: incidence, morphology, clinical features, and pathogenesis. Am J Kidney Dis 9 (1987) 183-190
110. Noble-Jamieson G., Thiru S., Johnston P., et al. Glomerulonephritis with end-stage liver disease in childhood. Lancet 339 (1992) 706-707
111. Appel G. Viral infections and the kidney: HIV, hepatitis B, and hepatitis C. Cleve Clin J Med 74 (2007) 353-360
112. Lai K.N., Tam J.S., Lin H.J., et al. The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B virus surface antigenaemia. Nephron 54 (1990) 12-17
113. Tang S., Lai F.M., Lui Y.H., et al. Lamivudine in hepatitis B-associated membranous nephropathy. Kidney Int 68 (2005) 1750-1758
114. Daghestani L., and Pomeroy C. Renal manifestations of hepatitis C infection. Am J Med 106 (1999) 347-354
115. Lauer G.M., and Walker B.D. Hepatitis C virus infection. N Engl J Med 345 (2001) 41-52
116. Agnello V., Chung R.T., and Kaplan L.M. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 327 (1992) 1490-1495
117. Alric L., Plaisier E., Thebault S., et al. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis 43 (2004) 617-623
118. Sansonno D., De Re V., Lauletta G., et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101 (2003) 3818-3826
119. Santostefano M., Zanchelli F., Zaccaria A., et al. The ultrastructural basis of renal pathology in monoclonal gammopathies. J Nephrol 18 (2005) 659-675
120. Duffy J.L., Khurana E., Susin M., et al. Fibrillary renal deposits and nephritis. Am J Pathol 113 (1983) 279-290
121. Korbet S.M., and Schwartz M.M. Multiple myeloma. J Am Soc Nephrol 17 (2006) 2533-2545
122. Blade J., Fernandez-Llama P., Bosch F., et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 158 (1998) 1889-1893
123. Montseny J.J., Kleinknecht D., Meyrier A., et al. Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transplant 13 (1998) 1438-1445
124. Leung N., and Rajkumar S.V. Renal manifestations of plasma cell disorders. Am J Kidney Dis 50 (2007) 155-165
125. Pozzi C., Pasquali S., Donini U., et al. Prognostic factors and effectiveness of treatment in acute renal failure due to multiple myeloma: a review of 50 cases. Report of the Italian Renal Immunopathology Group. Clin Nephrol 28 (1987) 1-9
126. Clark W.F., Stewart A.K., Rock G.A., et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 143 (2005) 777-784
127. Dember L. Amyloidosis-associated kidney disease. J Am Soc Nephrol 17 (2006) 3458-3471
128. Jaccard A., Moreau P., Leblond V., et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 357 (2007) 1083-1093
129. Pozzi C., D'Amico M., Fogazzi G.B., et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis 42 (2003) 1154-1163
130. Lin J., Markowitz G.S., Valeri A.M., et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 12 (2001) 1482-1492
131. Hill P.G., Forsyth J.M., Rai B., et al. Serum free light chains: an alternative to the urine Bence Jones proteins screening test for monoclonal gammopathies. Clin Chem 52 (2006) 1743-1748
132. Gertz M.A., and Kyle R.A. Hyperviscosity syndrome. J Intensive Care Med 10 (1995) 128-141